Die Wirksamkeit nicht-medikamentöser Zusatzinterventionen während der First-Line Therapie von Patienten mit Lungenkarzinom – Eine Feasibility Studie zum ACCEPT-Programm (12 Wochen multimodales Interventionskonzept)

Grah, Christian; Wüstefeld, H; Kurzeja, A; Eichberger, A; Stöck, Ivonne; Steinert, M.; Kalusa, K; Zimmermann, Camilla; Kokulinky, S; Stenzel, Nikola

doi:10.1055/s-0039-1678071

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACCEPT ® was developed between 2012 and 2017 and has since been stepwise implemented in clinical everyday practice, followed by a systematic evaluation, the results of which have first been presented in 2018 [35]. A prior interim evaluation of ACCEPT ® included a subgroup (n = 10) of the patients participating in the present study [51]. Here, the feasibility of ACCEPT ® was tested.…”

Section: Introductionmentioning

confidence: 99%

ACCEPT®: A Complementary Anthroposophical Program for the Palliative Treatment of Lung Cancer – Rationale and a Randomized Feasibility Study

et al. 2021

View full text Add to dashboard Cite

Background: Lung cancer is the oncological disease with the highest mortality worldwide. Health-related quality of life is severely compromised in the majority of patients. While the efficacy of early palliative psychosocial therapy has been demonstrated in several recent studies, appropriate therapy modules could so far not be integrated into daily practice of care. Therefore, an additive multimodal treatment concept for oncological centers was drafted: the Additive anthroposophic integrative medicine Cancer Concept of Early supportive or Palliative lung cancer Treatment (ACCEPT®). Patients and Methods: The first module consisted of a 3-month health education program, the second module was a concept of psychosocial interventions, and the third module was a supervised home training program. Between 2017 and 2018, 20 lung cancer patients (UICC IIIB/IV) were included and randomly assigned to treatment (n = 10) or a waiting control group (n = 10). The treatment group started ACCEPT® for 3 months immediately after diagnosis and received also standard oncological care (SOC) while the waiting control group received SOC only for 3 months, followed by ACCEPT® after this period. Health-related quality of life, disease management, disease-specific symptoms, and feasibility of the ACCEPT® were monitored at 4 time points. Results: 7 out of 10 patients in the treatment group (3 dropped out) and 6 out of 10 in the waiting control group (4 died during the intervention) completed treatment. Discussion/Conclusion: Lung cancer patients with high symptom load may benefit from ACCEPT®. The feasibility of this adjunctive therapy was demonstrated. The combination of SOC and ACCEPT® is feasible and applicable to a heterogeneous patient group and should be further evaluated with respect to efficacy and dosing.

show abstract

Section: Introductionmentioning

confidence: 99%